Standard BioTools Q3: $559M Liquidity, $30M Illumina Gain Ahead of Nov 19 Merger Vote
LAB is trading near its 52-week low of $0.588 (3.9% above the low).
Summary
Standard BioTools posted a $15.0M continuing-operations loss on flat $19.4M revenue, but a $30.0M Illumina termination payment and $559.4M of liquidity frame a quarter that is really about the November 19 Treeline merger vote.
Key Events · Earnings and Guidance · LAB
-
Q3 Continuing Ops Loss Narrows
Continuing operations lost $15.0M on $19.4M revenue, versus a $32.9M loss a year ago; nine-month revenue was $60.6M, down 1%.
-
$30M Illumina Termination Gain
Waiving the 2026 earnout and royalty/license agreements brought $30.0M cash, lifting nine-month pre-tax gain on the SomaScan sale to $202.3M.
-
Liquidity Jumps to $559.4M
Cash, equivalents and investments rose to $559.4M from $213.3M at year-end 2025; management says this funds operations for at least 12 months.
-
Treeline Merger Vote Nov 19
Stockholders vote November 19, 2026 on the all-stock Treeline merger; existing holders would own about 16% of the combined company, with closing expected in Q4 2026.
Analysis · LAB · Life Sciences
The quarter's headline numbers are transitional rather than operational: continuing operations lost $15.0M on $19.4M of revenue (down 1% year over year), but a $30.0M payment from Illumina for waiving the 2026 earnout pushed discontinued operations to a $28.5M gain and total net income to $13.5M. The balance sheet is the real story — $559.4M of cash and investments after the SomaScan sale proceeds, which comfortably funds operations for at least the next 12 months. Everything now hinges on the November 19, 2026 stockholder vote on the all-stock Treeline merger, where existing holders keep only about 16% of the combined company, and on the pending $5.5M Mass Cytometry sale that closes only if that merger closes.
How filings like this one have moved
In the 30 days to Nov 3, 2026, 32.3% of the 2077 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, LAB was trading at $0.61 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $241.1M. The 52-week trading range was $0.59 to $1.72. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.